PHLDB1

PHLDB1 (also known as LL5α) is a PH-domain-containing scaffold protein that senses phosphoinositides at the plasma membrane and organizes signaling and cytoskeletal complexes to control insulin-dependent glucose uptake and cell migration. Its PH domain binds PI(3,4)P2, PI(3,5)P2, and PI(3,4,5)P3, mediating insulin-stimulated translocation to the plasma membrane in adipocytes where it is required for Akt phosphorylation, p70 S6K activation, and isoform-specific GLUT4 translocation (PMID:20587420). At the leading edge of migrating cells, PHLDB1 assembles with liprin-α1 and ERC1a into a complex that sustains lamellipodial persistence, promotes active integrin β1 internalization, and supports tumor cell invasion (PMID:24982445). Biallelic loss-of-function frameshift variants in PHLDB1 cause autosomal recessive osteogenesis imperfecta (PMID:36543534).

1. 2003 Low

   Computational domain analysis established that PHLDB1 encodes a multi-domain protein with an FHA domain, SMC domain, and a PH domain homologous to the PIP3 sensor LL5β, predicting a signaling role that awaited experimental validation.

   Evidence In silico sequence and domain analysis with cDNA assembly

   PMID:14532993

   Open questions at the time

   • Purely computational prediction with no experimental validation in this study
   • Lipid-binding specificity of the PH domain was not tested
   • No cellular function assigned
2. 2010 High

   Direct biochemical and functional experiments answered the central question of what PHLDB1 does at the plasma membrane: its PH domain binds PI(3,4,5)P3 and related phosphoinositides, and PHLDB1 is required downstream of IRS-1 for insulin-stimulated Akt phosphorylation, GLUT4 translocation, and glucose uptake — with isoform specificity over PHLDB2.

   Evidence PH domain lipid-binding assays, live-cell imaging in adipocytes, siRNA knockdown of PHLDB1 vs PHLDB2, phospho-Akt/p70S6K western blots, GLUT4 translocation and deoxyglucose transport assays, adenoviral rescue

   PMID:20587420

   Open questions at the time

   • Direct binding partners linking PH-domain engagement to Akt activation were not identified
   • In vivo metabolic phenotype of PHLDB1 loss was not assessed
   • Mechanism by which PHLDB1 specifically promotes GLUT4 vesicle fusion was not resolved
3. 2014 High

   Beyond metabolic signaling, PHLDB1 was shown to organize a leading-edge complex with liprin-α1 and ERC1a that sustains lamellipodial dynamics, active integrin β1 endocytosis, and cell migration/invasion — establishing a second major functional axis for this scaffold.

   Evidence siRNA depletion in migrating cells, live-cell migration and Matrigel invasion assays, integrin β1 internalization assay, confocal imaging of polarized leading-edge structures

   PMID:24982445

   Open questions at the time

   • Whether PI(3,4,5)P3 binding by the PH domain is required for leading-edge complex assembly was not directly tested
   • The structural basis of PHLDB1–liprin-α1–ERC1a complex formation is unknown
   • Contribution of PHLDB1 to in vivo tumor metastasis was not demonstrated
4. 2015 Medium

   PHLDB1 knockdown was linked to altered tumor cell behavior in a glioma-associated 11q23.3 locus alongside DDX6, though the specific mechanistic contribution of PHLDB1 to gliomagenesis remained unclear.

   Evidence siRNA knockdown in 3D growth/invasion assays, luciferase enhancer scanning, chromatin conformation capture (3C)

   PMID:26610392

   Open questions at the time

   • PHLDB1 knockdown phenotype was not mechanistically dissected in glioma cells
   • The functional SNP-enhancer interaction mapped to DDX6 rather than PHLDB1
   • No separation of PHLDB1 vs DDX6 contribution at the molecular level
5. 2022 Medium

   Human genetic evidence established that biallelic loss-of-function of PHLDB1 causes autosomal recessive osteogenesis imperfecta, connecting the scaffold's signaling functions to bone homeostasis.

   Evidence Whole-exome sequencing of affected individuals, RT-PCR and western blot confirmation of PHLDB1 loss in patient fibroblasts

   PMID:36543534

   Open questions at the time

   • Mechanism linking PHLDB1 loss to impaired bone formation was inferred from prior Akt-signaling data rather than demonstrated in osteoblasts or bone tissue
   • No animal model of PHLDB1 loss-of-function bone phenotype reported
   • Whether the migration/integrin-trafficking axis also contributes to the bone phenotype is unknown

• Key open questions include the structural basis of PHLDB1 scaffold assembly, whether its PI(3,4,5)P3-sensing and leading-edge organizing functions are mechanistically coupled, and how PHLDB1 loss specifically impairs osteoblast or bone matrix biology to cause osteogenesis imperfecta.
• No structural model of full-length PHLDB1 or its domain-mediated interactions
• Direct demonstration of PHLDB1 function in bone-forming cells is lacking
• In vivo metabolic and skeletal phenotypes of PHLDB1 knockout animals have not been reported